Drug interactions
Erdafitinib + Linagliptin-metformin
Severity: Moderate
Erdafitinib and Linagliptin-metformin: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Erdafitinib may inhibit OCT2 and raise metformin exposure, increasing gastrointestinal effects and, rarely, lactic acidosis. The clinical importance is greater with renal impairment.
What this interaction means in plain words
Erdafitinib and Linagliptin-metformin can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Erdafitinib belongs to Oncology; Linagliptin-metformin belongs to Endocrine.
Why it happens
Erdafitinib inhibits OCT2-mediated renal secretion of metformin.
What to do
Monitor glycemic control and metformin tolerability, and reduce the metformin dose if adverse effects occur. Check renal function periodically.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Erdafitinib and Linagliptin-metformin, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Linagliptin-metformin
Other interactions of Erdafitinib
Frequently asked questions
Can I take Erdafitinib with Linagliptin-metformin?
MediHelp rates the interaction as moderate. Erdafitinib and Linagliptin-metformin can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Erdafitinib may inhibit OCT2 and raise metformin exposure, increasing gastrointestinal effects and, rarely, lactic acidosis. The clinical importance is greater with renal impairment.
How serious is the interaction between Erdafitinib and Linagliptin-metformin?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor glycemic control and metformin tolerability, and reduce the metformin dose if adverse effects occur. Check renal function periodically.
What other medicines interact with Linagliptin-metformin?
MediHelp also lists interactions of Linagliptin-metformin with, for example, Apalutamide, Carbamazepine, Contrast media. The full list is on the Linagliptin-metformin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
